Ultimately, ten genes AKT1, PPARG, PTGS2, EGFR, ESR1, JAK2, MAPK1, PARP1, GSK3B, PPARA were found to be the primary therapeutic targets of Crateva’s activities against DN. This evidence concerns the gene PARP1 and liver dysplastic nodule.